The increasingly popular class of GLP-1 receptor and GIP dual medications, such as tirzepatide, semaglutide, and the newly introduced retatrutide, provide groundbreaking improvements in diabetes management https://tirzepatide145957.activablog.com/42549847/semaglutide-a-comparative-look